Herpes Zoster (Shingles) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 61 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Herpes Zoster (Shingles) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Herpes Zoster (Shingles) - Pipeline Review, H2 2014', provides an overview of the Herpes Zoster (Shingles)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Herpes Zoster (Shingles) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Herpes Zoster (Shingles) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Herpes Zoster (Shingles) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Herpes Zoster (Shingles) Overview 7
Therapeutics Development 8
Pipeline Products for Herpes Zoster (Shingles) - Overview 8
Pipeline Products for Herpes Zoster (Shingles) - Comparative Analysis 9
Herpes Zoster (Shingles) - Therapeutics under Development by Companies 10
Herpes Zoster (Shingles) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Herpes Zoster (Shingles) - Products under Development by Companies 16
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development 17
GlaxoSmithKline plc 17
Merck & Co., Inc. 18
Astellas Pharma Inc. 19
Foamix Ltd. 20
Arcion Therapeutics, Inc. 21
Epiphany Biosciences, Inc. 22
NAL Pharmaceuticals Ltd. 23
Herpes Zoster (Shingles) - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
amenamevir - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
GSK-1437173A - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
V-212 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
FV-100 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
valomaciclovir stearate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
lidocaine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
acyclovir - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NAL-3221 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NAL-3223 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Herpes Zoster (Shingles) - Recent Pipeline Updates 46
Herpes Zoster (Shingles) - Dormant Projects 50
Herpes Zoster (Shingles) - Discontinued Products 51
Herpes Zoster (Shingles) - Product Development Milestones 52
Featured News & Press Releases 52
Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster And Post-herpetic Neuralgia In Older US Population, Cohort Study Finds 52
Jul 18, 2012: Agenus Annnounces Intiation Of Phase III Clinical Trial Of GSK's Herpes Zoster Vaccine Candidate In Immunocompromised Patients 53
Jun 05, 2012: Kaiser Permanente Study Shows GSK's Zoster Lowers Short-Term Risk Of Shingles Recurrence 54
Feb 01, 2012: Asahi Kasei Pharma Files Application For Approval Of Famvir Anti-herpes Agent For Additional Indication 55
Dec 13, 2010: Inhibitex Reports Promising Top-Line Results From Phase II Shingles Trial With FV-100 56
Oct 15, 2010: Inhibitex Completes Enrollment In Phase II Clinical Trial Of FV-100 In Shingles Patients 57
Aug 23, 2010: GSK Initiates Phase III Clinical Trials To Develop Herpes Zoster Vaccine For Prevention Of Shingles 57
Jul 22, 2010: Inhibitex Reports Independent Data Safety Monitoring Board Recommends Continuation Of Phase II Clinical Trial Of FV-100 58
Nov 18, 2009: Epiphany Announces Positive Results Of Its Drug Candidate Valomaciclovir From Its Phase 2b Trial In Shingles 58
Sep 09, 2008: Epiphany Biosciences Announces To Continue Phase 2 shingles Study After Interim Analysis 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Number of Products under Development for Herpes Zoster (Shingles), H2 2014 8
Number of Products under Development for Herpes Zoster (Shingles) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Comparative Analysis by Unknown Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline plc, H2 2014 17
Herpes Zoster (Shingles) - Pipeline by Merck & Co., Inc., H2 2014 18
Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc., H2 2014 19
Herpes Zoster (Shingles) - Pipeline by Foamix Ltd., H2 2014 20
Herpes Zoster (Shingles) - Pipeline by Arcion Therapeutics, Inc., H2 2014 21
Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences, Inc., H2 2014 22
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd., H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Number of Products by Stage and Target, H2 2014 26
Number of Products by Stage and Mechanism of Action, H2 2014 28
Number of Products by Stage and Route of Administration, H2 2014 30
Number of Products by Stage and Molecule Type, H2 2014 32
Herpes Zoster (Shingles) Therapeutics - Recent Pipeline Updates, H2 2014 46
Herpes Zoster (Shingles) - Dormant Projects, H2 2014 50
Herpes Zoster (Shingles) - Discontinued Products, H2 2014 51